Our Commission intends to revise certain provisions regarding recombinant therapeutic biological products. To ensure the scientific rigor, rationality, and applicability of the standards, we hereby solicit comments from all sectors of society (see attached details). The public consultation period shall be three months. Relevant entities are requested to carefully review the draft. If there are any objections, please submit written feedback in a timely manner, accompanied by relevant explanations, experimental data, and contact information. Correspondence must bear the official seal. The recipient unit is the “Office of the Chinese Pharmacopoeia Commission.” Meanwhile, please send an electronic scanned copy of the official letter to the designated email address. Failure to respond within the public consultation period shall be deemed as no objection to the draft standards for public consultation.Contact: Zhao Yuhao
Tel: 010-67079634
Email: zhaoyuhao@chp.org.cn
Address: Office of the Chinese Pharmacopoeia Commission (Building 11, Fahuang Nanli, Dongcheng District, Beijing)
Postal Code: 100061
Attachment: Revised Draft for Public Comment on Recombinant Therapeutic Biological Products.pdf
Chinese Pharmacopoeia Commission
July 15, 2019
